Citations

Clear

1053 citation(s) found for "Andre, F".

Identification of Immunoreactive Regions of Homology between Soluble Epidermal Growth Factor Receptor and α5-Integrin
Wilken, Jason A. , Baron, Andre T. , Foty, Ramsey A. , Maihle, Nita J. , McCormick, Daniel

Mayo Clinic

Biochemistry | April 14, 2011 | Volume: 50 | Issue: 20 | Pages: 4309-4321

10.1021/bi200126j | PMID 21491912 Get It

Abstract 4649: Comprehensive isoform expression analysis reveals that EGFR and sEGFR are prognostic determinants of cancer
Singh, Meenakshi , Maihle, Nita J. , Wilken, Jason A. , Baron, Andre T. , McCormick, Daniel

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 4649-4649

10.1158/1538-7445.am10-4649 Get It

Abstract In July, 2009 the United States’ Food and Drug Agency (FDA) approved the use of a new biologically-targeted drug called ‘cetuximab’ (Erbitux) for the treatment of patients with advanced colorectal cancer (CRC). Cetuximab is a chimeric antibody directed against the extracellular domain of the epidermal growth factor receptor (EGFR). Paradoxically, EGFR expression, as it is currently measured by commercially available assays, has not been useful for predicting who will respond to cetuximab. We propose that one problem with these assays is their inability to measure EGFR and soluble EGFR (sEGFR) isoforms independently. We previously have documented the expression of an sEGFR isoform in human tissues (1), and have generated antibodies directed against a 31-mer peptide (residues 604-634) located within the unique 78 amino acid carboxy-terminal sequence of sEGFR (2). Interestingly, this anti-sEGFR antibody recognizes a second protein of ∼140-kDa (p140), which we have identified as human α5-integrin. Biochemical and mass spectrometry analyses show that a short region in the calf domain of α5-integrin shares sequence identity with the 31-mer sEGFR peptide. We have used this 31-mer antibody with an antibody directed against the intracellular domain of full-length EGFR to develop a novel EGFR vs. sEGFR/α5-integrin expression assay. This assay demonstrates that sEGFR/α5-integrin is co-expressed with EGFR in normal as well as malignant tissues, including in a number of carcinoma-derived cell lines. We also observe that high expression of EGFR and sEGFR/α5-integrin in a large cohort of ovarian cancer patients defines a strong adverse prognostic determinant of survival. These results implicate EGFR, sEGFR, and integrins as cancer biomarkers and demonstrate the critical importance of independently assessing both full-length and soluble EGFR isoforms in prognostic EGFR expression assays. *–JAW and ATB contributed equally to this study (1). Reiter et al. (2001) Genomics. 71(1):1-20 (2). Christensen et al. (2002) Hybrid Hybridomics. 21(3):183-9 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4649.
MicroRNA Signatures as Diagnostic and Therapeutic Targets
Waldman, Scott A. , Terzic, André

Mayo Clinic

Laboratory Medicine Online | January 20, 2011 | Volume: 1 | Issue: 1 | Pages: 1

10.3343/lmo.2011.1.1.1 Get It

The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss
Pratap, Jitesh , Akech, Jacqueline, Wixted, John J. , Szabo, Gabriela, McGee‐Lawrence, Meghan E. , Bedard, Krystin, Dhillon, Robinder J., Wijnen, André J. van , Stein, Janet L. , Westendorf, Jennifer J., Lian, Jane B. , Hussain, Sadiq , Li, Xiaodong , Stein, Gary S. , van Wijnen, Andre J , McGee-Lawrence, Meghan E

Mayo Clinic

Molecular Cancer Therapeutics | December 15, 2010 | Volume: 9 | Issue: 12 | Pages: 3210-3220

10.1158/1535-7163.mct-10-0572 | PMID 21159607 Get It

AbstractVorinostat, an oral histone deacetylase inhibitor with antitumor activity, is in clinical trials for hematologic and solid tumors that metastasize and compromise bone structure. Consequently, there is a requirement to establish the effects of vorinostat on tumor growth within bone. Breast (MDA-231) and prostate (PC3) cancer cells were injected into tibias of SCID/NCr mice and the effects of vorinostat on tumor growth and osteolytic disease were assessed by radiography, micro-computed tomography, and histologic and molecular analyses. Vorinostat-treated and control mice without tumors were also examined. Tumor growth in bone was reduced ∼33% by vorinostat with inhibited osteolysis in the first few weeks of the experiment. However, osteolysis became more severe in both the vehicle and vorinostat-treated groups. Vorinostat increased the expression of tumor-derived factors promoting bone resorption, including PTHrP, IL-8, and osteopontin. After 4 weeks of vorinostat therapy, the non–tumor-bearing contralateral femurs and limbs from vorinostat-treated tumor-free SCID mice showed significant bone loss (50% volume density of controls). Thus, our studies indicate that vorinostat effectively inhibits tumor growth in bone, but has a negative systemic effect reducing normal trabecular bone mass. Vorinostat treatment reduces tumor growth in bone and accompanying osteolytic disease as a result of decreased tumor burden in bone. However, vorinostat can promote osteopenia throughout the skeleton independent of tumor cell activity. Mol Cancer Ther; 9(12); 3210–20. ©2010 AACR.
Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability
Crespo‐Diaz, Ruben , Behfar, Atta , Butler, Greg W., Padley, Douglas, Sarr, Michael G., Bartunek, Jozef, Dietz, Allan B. , Terzic, André , Behfar, Atta , Dietz, Allan B

Mayo Clinic

Cell Transplantation | December 7, 2010 | Volume: 20 | Issue: 6 | Pages: 797-812

10.3727/096368910x543376 | PMID 21092406 Get It

With favorable regenerative and immunotolerant profiles, patient-derived human mesenchymal stem cells (hMSCs) are increasingly considered in cell therapy. Derived from bone marrow (BM) and standardized with culture in fetal bovine serum (FBS), translation of hMSC-based approaches is impeded by protracted expansion times, risk of xenogenic response, and exposure to zoonoses. Here, human platelet lysate adherent to good manufacturing practices (GMP-hPL) provided a nonzoonotic adjuvant that enhanced the capacity of BM-hMSC to proliferate. The nurturing benefit of GMP-hPL was generalized to hMSC from adipose tissue evaluated as an alternative to bone marrow. Long-term culture in GMP-hPL maintained the multipotency of hMSC, while protecting against clonal chromosomal instability detected in the FBS milieu. Proteomic dissection identified TGF-β, VEGF, PDGF, FGF, and EGF as highly ranked effectors of hPL activity, revealing a paradigm of healing that underlies platelet lysate adjuvancy. Thus, GMP-adherent human platelet lysate accelerates hMSC proliferation with no chromosomal aberrancy, through an innate repair paradigm.
Translational Medicine: Path to Personalized and Public Health
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Mayo Clinic

Biomarkers in Medicine | December 6, 2010 | Volume: 4 | Issue: 6 | Pages: 787-790

10.2217/bmm.10.101 | PMID 21133696 Get It

Channelopathies: Decoding Disease Pathogenesis
Pérez-Terzic, Carmen, Terzic, André

Mayo Clinic

Science Translational Medicine | July 29, 2010 | Volume: 2 | Issue: 42 | Pages: No page available

10.1126/scitranslmed.3001433 | PMID 20668296 Get It

New research stratifies the origin of an inherited multisystem channelopathy, a finding that has implications for personalized diagnosis and therapy.
ATP-Sensitive K+ Channel-Deficient Dilated Cardiomyopathy Proteome Remodeled by Embryonic Stem Cell Therapy  
Zlatkovic‐Lindor, Jelena, Arrell, D. Kent , Nelson, Timothy J. , Yamada, Satsuki , Terzic, André , Nelson, Timothy J

Mayo Clinic

Stem Cells | June 22, 2010 | Volume: 28 | Issue: 8 | Pages: 1355-1367

10.1002/stem.465 | PMID 20572010 Get It

Abstract Transplantation of pluripotent stem cells has proven beneficial in heart failure, yet the proteomic landscape underlying repair remains largely uncharacterized. In a genetic model of dilated cardiomyopathy elicited by pressure overload in the KCNJ11 (potassium inwardly rectifying channel, subfamily J, member 11) null mutant, proteome-wide profiles were here resolved by means of a systems approach prior to and following disease manifestation in the absence or presence of embryonic stem cell treatment. Comparative two-dimensional gel electrophoresis revealed a unique cardiomyopathic proteome in the absence of therapy, remodeled in response to stem cell treatment. Specifically, linear ion trap quadrupole-Orbitrap mass spectrometry determined the identities of 93 and 109 differentially expressed proteins from treated and untreated cardiomyopathic hearts, respectively. Mapped protein–protein relationships and corresponding neighborhoods incorporated the stem cell-dependent subproteome into a nonstochastic network with divergent composition from the stem cell-independent counterpart. Stem cell intervention produced a distinct proteome signature across a spectrum of biological processes ranging from energetic metabolism, oxidoreductases, and stress-related chaperones to processes supporting protein synthesis/degradation, signaling, and transport regulation, cell structure and scaffolding. In the absence of treatment, bioinformatic interrogation of the disease-only proteome network prioritized adverse cardiac outcomes, ablated or ameliorated following stem cell transplantation. Functional and structural measurements validated improved myocardial contractile performance, reduced ventricular size and decreased cardiac damage in the treated cohort. Unbiased systems assessment unmasked “cardiovascular development” as a prioritized biological function in stem cell-reconstructed cardiomyopathic hearts. Thus, embryonic stem cell treatment transformed the cardiomyopathic proteome to demote disease-associated adverse effects and sustain a procardiogenic developmental response, supplying a regenerative substrate for heart failure repair.
Decoded Calreticulin-Deficient Embryonic Stem Cell Transcriptome Resolves Latent Cardiophenotype
Faustino, Randolph S. , Chiriac, Anca , Niederländer, Nicolas J. , Nelson, Timothy J. , Behfar, Atta , Mishra, Prasanna K. , Pérez-Terzic, Carmen, Macura, Slobodan , Michalak, Marek , Terzic, André , Behfar, Atta , Nelson, Timothy J

Mayo Clinic

Stem Cells | May 23, 2010 | Volume: 28 | Issue: 7 | Pages: 1281-1291

10.1002/stem.447 | PMID 20506533 Get It

Abstract Genomic perturbations that challenge normal signaling at the pluripotent stage may trigger unforeseen ontogenic aberrancies. Anticipatory systems biology identification of transcriptome landscapes that underlie latent phenotypes would offer molecular diagnosis before the onset of symptoms. The purpose of this study was to assess the impact of calreticulin-deficient embryonic stem cell transcriptomes on molecular functions and physiological systems. Bioinformatic surveillance of calreticulin-null stem cells, a monogenic insult model, diagnosed a disruption in transcriptome dynamics, which re-prioritized essential cellular functions. Calreticulin-calibrated signaling axes were uncovered, and network-wide cartography of undifferentiated stem cell transcripts suggested cardiac manifestations. Calreticulin-deficient stem cell-derived cardiac cells verified disorganized sarcomerogenesis, mitochondrial paucity, and cytoarchitectural aberrations to validate calreticulin-dependent network forecasts. Furthermore, magnetic resonance imaging and histopathology detected a ventricular septal defect, revealing organogenic manifestation of calreticulin deletion. Thus, bioinformatic deciphering of a primordial calreticulin-deficient transcriptome decoded at the pluripotent stem cell stage a reconfigured multifunctional molecular registry to anticipate predifferentiation susceptibility toward abnormal cardiophenotype.
Clinical Pharmacology: A Paradigm for Individualized Medicine
Waldman, Scott A. , Kraft, Walter K. , Nelson, Timothy J. , Terzic, André , Nelson, Timothy J , Waldman, Scott A

Mayo Clinic

Biomarkers in Medicine | December 15, 2009 | Volume: 3 | Issue: 6 | Pages: 679-684

10.2217/bmm.09.76 | PMID 20477706 Get It